Skip to content
VistoaGuestSign in to save
HomeTopicsSearchSavedMe
Now trendingCoverage GapsMethodologySettingsHelp

USA Today

May 4, 2026

Ashley Graham calls GLP-1s 'smack in the face' to women
USA Todayby David Oliver·May 4, 2026

Ashley Graham calls GLP-1s 'smack in the face' to women

Political leann/a
  • Home
  • Search
  • Saved
  • Me
Source qualityn/a
Factual ration/a
Framingn/a

May 4, 2026, 8:37 a.m. ETAshley Graham has a bone to pick with GLP-1s. Specifically, how they're ushering in a new wave of thinness on runways again.“It's really disheartening,” the model, 38, recently told Marie Claire. “There was a pendulum that swung that was so body acceptance, positivity, everybody be who they want to be. And now it's going back this whole opposite way that feels like a smack in the face to the women who have felt like they've had a voice.”For those who need them, GLP-1 injections can be a life-changing tool and lead to significant health benefits, particularly for those with diabetes. Approximately 1 in 8 adults in the United States has used one for diabetes, heart disease or weight loss. But now with FDA-approved weight loss pills on the market, some mental health and eating disorder experts are concerned that the prevalence of these medications are a return to a time where diet culture is everywhere, and they worry people with a history of disordered eating may seek out GLP-1s in pill form as they become a cultural norm.That's not to say that progress is over and you'll never see a plus-size model again. “It goes

Read at USA TodayCompare full coverage

Lean: n/a · Source quality n/a · Factual vs opinion n/a.

Full coverage

See full cluster →

Left 0

  • No coverage

Center 2

  • Ashley Graham calls GLP-1s 'smack in the face' to women

    USA Today · 5h

  • Supermodel slams GLP-1 trend, says weight loss shots are a 'smack in the face' to body positivity movement

    Fox News · 18h

Right 0

  • No coverage

Score signature

Political lean

Political leann/aSource qualityn/aFactual ration/aFramingn/a
100
Source diversity
across 2 outlets
Compare full coverage